アップロードされた3つのファイルの最後の条文は以下の通りです。

* **UK Biobank (mta_ukbb_7-9.md)**: Clause 9.6
* **EGA (mta_ega.md)**: Clause 19
* **NIH (mta_nih.md)**: Clause 10

***

## 7. Annual Confirmation and Audit
* **UKBB 7.1** During the Term, UK Biobank requires the Applicant Pl to confirm on an annual basis that the Approved Research Project remains compliant with the provisions of the MTA (and the Annexes). Specifically, the Applicant PI shall provide UK Biobank with such confirmation as part of the Annual Project Report in the form attached at Annex 3. In the event that the Annual Project Report is not received by UK Biobank in the timeframe, manner and form prescribed, UK Biobank reserves the rights set out in clause 5.5 above.
    * **対応するEGAの条文（英）**:
        * ありません。
    * **対応するNIHの条文（英）**:
        * ありません。

* **UKBB 7.2** In circumstances where UK Biobank reasonably believes that a Data Security Incident or other serious incident has occurred then, on notice to the Applicant, in order to confirm or investigate compliance with the provisions of this MTA, UK Biobank may itself or via appropriate third parties:
    * **UKBB 7.2.1** choose to undertake an audit (either in person or remotely) in order to review the security, storage or other arrangements for the Materials; and
    * **UKBB 7.2.2** request such additional information about the Approved Research Project and/or its progress as UK Biobank may, from time to time, reasonably require.
    * **対応するEGAの条文（英）**:
        * **EGA 17**: If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement.
        * **比較結果**: 部分一致
        * **判断理由**: UKBBは「データセキュリティインシデントまたはその他の重大なインシデント」という特定の状況下で監査を行う権利を定めているのに対し、EGAは「要求された場合」というより一般的な状況でデータセキュリティと管理の文書の検査を許可することに同意すると定めています。ただし、両者ともデータセキュリティや契約遵守を確認するための監査・検査権について述べています。

    * **対応するNIHの条文（英）**:
        * **NIH 1.h**: Registry (or its agents) may audit Researcher's use of the Data to ensure compliance with this Agreement. Any such audits will be conducted during Researcher's regular business hours with reasonable advanced notice and consideration for Researcher's business operations. Researcher will cooperate, and will ensure that all Researcher personnel will cooperate, with the auditors and will make all records and materials available to them.
        * **比較結果**: 一致
        * **判断理由**: 両者は、契約遵守を確実にするために、提供者が被提供者に対して監査を実施できるという点について、ほぼ同じ内容を規定しています。UKBBはセキュリティインシデントを理由として挙げていますが、NIHはより一般的な契約遵守を目的としています。しかし、監査の目的が「遵守の確認」であるという点で本質的に一致しています。

* **UKBB 7.3** UK Biobank shall bear the costs of such audits unless a material default within the procedures and processes of the relevant Applicant is discovered, in which case the relevant Applicant shall be obliged to reimburse the reasonable costs of UK Biobank and any relevant third parties.
    * **対応するEGAの条文（英）**:
        * ありません。
    * **対応するNIHの条文（英）**:
        * ありません。

* **UKBB 7.4** UK Biobank confirms that its audit rights shall be exercisable no more than once a year and on the provision of reasonable notice (which may be immediate in the event of a Data Security Incident or other serious incident) to the Applicant. As far as practically possible, UK Biobank agrees to coordinate any site visits and audits with the other relevant parties.
    * **対応するEGAの条文（英）**:
        * ありません。
    * **対応するNIHの条文（英）**:
        * **NIH 1.h**: Registry (or its agents) may audit Researcher's use of the Data to ensure compliance with this Agreement. Any such audits will be conducted during Researcher's regular business hours with reasonable advanced notice and consideration for Researcher's business operations. Researcher will cooperate, and will ensure that all Researcher personnel will cooperate, with the auditors and will make all records and materials available to them.
        * **比較結果**: 部分一致
        * **判断理由**: 両者とも監査を実施する際の「合理的な事前通知（reasonable advanced notice）」について言及しています。UKBBは年1回までという頻度の制限を明記し、重大なインシデントの場合は即時通知が可能と補足しています。NIHはより簡潔に、合理的な事前通知を規定しています。

***

## 8. Confidentiality
* **UKBB 8.1** Subject to the exceptions in clause 8.2, UK Biobank shall keep confidential any information disclosed to it in writing by the Applicant that is marked confidential ("Applicant's Confidential Information") and shall not disclose such information to any person.
    * **対応するEGAの条文（英）**:
        * **EGA 2**: The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. Without prejudice to the generality of the foregoing, the User Institution agrees to use at least the measures set out in Appendix I to protect these Data.
        * **比較結果**: 不一致
        * **判断理由**: UKBBの条文は、UK Biobankが申請者から受け取った機密情報を守る義務について述べています。一方、EGAの条文は、ユーザー機関が研究参加者のデータそのものの機密性を保護する義務について述べており、対象となる機密情報が異なります。

    * **対応するNIHの条文（英）**:
        * **NIH 7.b**: Researcher agrees that it will not disclose to others or use for its own benefit or the benefit of others, any Data or other Confidential Information disclosed by Registry in the course of this Agreement. For purposes of this Agreement, "Confidential Information" shall mean methods, processes, know-how, policies, procedures, templates, and other non-public confidential information of Registry. All Confidential Information is and shall remain the confidential property of Registry. Researcher shall keep the Confidential Information in strict confidence and may not use or otherwise disclose the Confidential Information to any third party without the prior written consent of Registry. Researcher shall notify Registry within [insert timeframe, e.g., two (2) business days] of any uses or disclosures of Confidential Information not permitted by this Agreement.
        * **比較結果**: 不一致
        * **判断理由**: UKBBの条文は、UK Biobankが申請者からの機密情報を守る義務を規定しています。一方、NIHの条文は、研究者がレジストリからの機密情報を守る義務を規定しており、立場が逆です。

* **UKBB 8.2** UK Biobank may disclose the Applicant's Confidential Information where expressly permitted by this MTA or when:
    * **UKBB 8.2.1** it is required to be disclosed by law, by any governmental or other regulatory authority, by a court or other authority of competent jurisdiction; or
    * **UKBB 8.2.2** it can be shown by UK Biobank (to the Applicant's reasonable satisfaction) to have been known by UK Biobank before disclosure to it by such Applicant; or
    * **UKBB 8.2.3** it was lawfully disclosed to UK Biobank by a third party who did not impose any restrictions on its disclosure; or
    * **UKBB 8.2.4** the information was in (or enters into) the public domain other than by reason of a breach of this clause by UK Biobank; or
    * **UKBB 8.2.5** UK Biobank and the Applicant agree, acting reasonably, that such information is trivial or obvious, or they agree in writing that such disclosure may be permitted.
    * **対応するEGAの条文（英）**:
        * ありません。
    * **対応するNIHの条文（英）**:
        * ありません。

***

## 9. Data Protection
* **UKBB 9.1** The parties acknowledge that UK Biobank and the Applicant are independent controllers with respect to the Participant Level Data that is processed in accordance with this MTA, and that the Applicant shall process the Participant Level Data strictly for the Permitted Purpose. In no event shall the parties process the Participant Level Data as joint controllers.
    * **対応するEGAの条文（英）**:
        * ありません。
    * **対応するNIHの条文（英）**:
        * **NIH 1.c**: Researcher shall perform the Research and use the Data in strict compliance with: (i) this Agreement; (ii) all applicable laws, rules and regulations (including but not limited to the Health Insurance Portability and Accountability Act of 1996 and all regulations implements thereunder, ("HIPAA"); (iii) all Registry policies, procedures, and governance documents made available to Researcher; (iv) all regulatory approval documents (including but not limited to approvals of Institutional Review Boards ("IRBs"), patient informed consent forms, and patient HIPAA authorization forms; and (v) any documentation submitted by Researcher to Registry in order to gain access to the Data (e.g., Data access request forms, Research proposals).
        * **比較結果**: 不一致
        * **判断理由**: UKBBの条文は、UK Biobankと申請者がデータ処理に関して「独立した管理者（independent controllers）」であると定義しています。一方、NIHの条文は、研究者がHIPAAを含むすべての適用法規を遵守してデータを使用する責任があることを規定しており、データ管理者の関係性については言及していません。

* **UKBB 9.2** Each party shall be individually and separately responsible for complying with the obligations that apply to it as a controller under Data Protection Legislation.
    * **対応するEGAの条文（英）**:
        * ありません。
    * **対応するNIHの条文（英）**:
        * **NIH 1.c**: Researcher shall perform the Research and use the Data in strict compliance with: (i) this Agreement; (ii) all applicable laws, rules and regulations (including but not limited to the Health Insurance Portability and Accountability Act of 1996 and all regulations implements thereunder, ("HIPAA"); (iii) all Registry policies, procedures, and governance documents made available to Researcher; (iv) all regulatory approval documents (including but not limited to approvals of Institutional Review Boards ("IRBs"), patient informed consent forms, and patient HIPAA authorization forms; and (v) any documentation submitted by Researcher to Registry in order to gain access to the Data (e.g., Data access request forms, Research proposals).
        * **比較結果**: 不一致
        * **判断理由**: UKBBの条文は、各当事者がデータ保護法制の下で管理者としての義務を個別に負うことを定めています。一方、NIHの条文は、研究者が適用される法令（HIPAAを含む）を遵守する義務について述べていますが、各当事者が「管理者」として個別に責任を負うという関係性には言及していません。

* **UKBB 9.3** In the event that the Applicant, Applicant PI or any Applicant Researcher receives any correspondence, enquiry or complaint from a Participant, regulator or other third party ("Correspondence") in connection with the processing of the Participant Level Data, it shall promptly inform UK Biobank giving full details of the same. In all circumstances, the Applicant, Applicant PI or any Applicant Researcher shall: (i) obtain UK Biobank's written approval before responding to the Correspondence, including approval of the contents of any response; and (ii) subject to Data Protection Legislation, permit UK Biobank to respond directly to the Correspondence.
    * **対応するEGAの条文（英）**:
        * ありません。
    * **対応するNIHの条文（英）**:
        * ありません。

* **UKBB 9.4** Where UK Biobank transfers Participant Level Data to an Applicant outside the UK to a territory that has not been specified as ensuring an adequate level of protection in accordance with Data Protection Legislation, the parties agree that the UK Addendum shall be automatically incorporated into this MTA by reference and deemed to be completed as set out in Part B of Annex 1 of this MTA.
    * **対応するEGAの条文（英）**:
        * ありません。
    * **対応するNIHの条文（英）**:
        * ありません。

* **UKBB 9.5** If there is any conflict between the MTA and the UK Addendum, the UK Addendum will prevail.
    * **対応するEGAの条文（英）**:
        * ありません。
    * **対応するNIHの条文（英）**:
        * ありません。

* **UKBB 9.6** The Applicant shall not process any Participant Level Data (nor permit any Participant Level Data to be processed) in a territory outside of the UK (or where clause 9.4 applies, where processing occurs in a subsequent territory) unless it has taken such measures as are necessary to ensure the transfer is in compliance with Data Protection Legislation.
    * **対応するEGAの条文（英）**:
        * **EGA 5**: The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorised Personnel. Should the User Institution wish to share these Data with an External Collaborator, the External Collaborator must complete a separate application for access to these Data.
        * **比較結果**: 不一致
        * **判断理由**: UKBBの条文は、データ保護法制を遵守しない限り、UK外の地域でデータを処理することを禁じています。一方、EGAの条文は、承認された人員以外へのデータ移転を禁じており、外部の共同研究者には別の申請が必要であると規定しています。両者の焦点は異なります。

    * **対応するNIHの条文（英）**:
        * ありません。

***

## 条文番号の対応表

| UKBBの条文番号 | EGAの条文番号 | NIHの条文番号 |
| :--- | :--- | :--- |
| 7.1 | なし | なし |
| 7.2 | 17 | 1.h |
| 7.3 | なし | なし |
| 7.4 | なし | 1.h |
| 8.1 | 2 | 7.b |
| 8.2 | なし | なし |
| 9.1 | なし | 1.c |
| 9.2 | なし | 1.c |
| 9.3 | なし | なし |
| 9.4 | なし | なし |
| 9.5 | なし | なし |
| 9.6 | 5 | なし |